The role of SNARE protein genes in the regulation of Von Willebrand Factor concentration and other coagulation factors

The role of SNARE protein genes in the regulation of Von Willebrand Factor concentration and other coagulation factors - SNARE proteins and VWF

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36387

Enrollment

100

Registered

2010-11-30

Start date

2011-03-18

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

increased inclination to clotting thrombofilia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Males and females - 18 - 35 years - Caucasians

Exclusion criteria

Exclusion criteria: - Known cardiovascular risk factors, such as hypertension, diabetes, hypercholesterolemia, obesity (BMI > 30 kg/m2), and a positive family history of CVD. - Smoking - Use of medication known to influence VWF levels, such as statins, beta-blockers etc. (oral contraceptive use is allowed). - Known malignancies, liver dysfunction or renal dysfunction. - Pregnancy - If the participant wishes not to be informed about clinically relevant abnormalities that could be detected during the study.

Design outcomes

Primary

Measure	Time frame
The VWF plasma concentration will change after heavy exercise and this change will differ among genotypes. We expect a 60% increase of VWF plasma levels after heavy exercise and approximately 30% difference between genotypes.	—

Secondary

Measure	Time frame
Other coagulation parameters and substances secreted by WPBs. To what extent does variation in skin-autofluorescence as a non-invasive marker for accumulation of advanced glycation endproducts and atherosclerotic processes explain the variance in the regulation of VWF concentration?	—

Countries

Netherlands

Outcome results